BioSpace News Archive

Core One Labs Inc. is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. has expanded its product commercialization team, adding Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs.

Apotheka Systems Inc. announced they have been awarded a critical Patent “Methods, Systems, and Storage Media For Managing Patient Information Using a Blockchain Network” by the U.S. Patent and Trademark Office (“USPTO”) U.S. Patent No. 10,885,170 issued on January 5th, 2021

Collaboration will integrate Microsoft Azure AI and Volastra’s insights into tumor biology to develop machine learning tools to detect drivers of tumor growth and predict metastatic risk

Shattuck Labs, Inc., a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, announced it will participate in Needham’s 20th Annual Healthcare Conference being held virtually April 12-15, 2021.

Novel Microdevices, Inc. ,(Novel) a developer of an innovative molecular diagnostics platform, announced today that CARB-X has awarded it up to $13 .8 million in non-dilutive funding to develop its next-generation rapid molecular test for the diagnosis of sexually transmitted bacterial infections, including Chlamydia trachomatis

Findings from an analysis of the first 500 patients enrolled in the SPHERE registry found more than three-quarters of pulmonary arterial hypertension patients treated with UPTRAVI® either maintained or reduced their one-year mortality risk score.

Valeo Pharma Inc . , a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.

PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced it will host an investor call on April 15, 2021 at 10 am AEST | 8 am AWST

Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21

Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced that it will present one oral and four poster presentations at the American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting (Week 1), taking place from April 10 to 15, 2021. Abstracts are available at: www.aacr.org .